On the stock market since 2018, it operates in the world of health and science. It has 60 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 75% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Revenue Growth: Sales are growing slowly.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $11K a year. A small number, but proof the product has real buyers.
There is $41.8M in the vault; even if every debt were paid off, $34.0M would remain.
Over the last 12 months, company executives reported 38 buys and 7 sells. Management buying with its own money is usually read as a good sign.
A loss of $131K against $11K in annual sales. And on top of that, sales fell from the year before.
The stock sits at $0.07. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.9 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, PHAS sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: PHAS is a high-risk stock — not yet profitable, and its future rides on its product catching on.